HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Retroelements (Retrotransposon)

Subscribe to New Research on Retroelements

Elements that are transcribed into RNA, reverse-transcribed into DNA and then inserted into a new site in the genome. Long terminal repeats (LTRs) similar to those from retroviruses are contained in retrotransposons and retrovirus-like elements. Retroposons, such as LONG INTERSPERSED NUCLEOTIDE ELEMENTS and SHORT INTERSPERSED NUCLEOTIDE ELEMENTS do not contain LTRs.

Also Known As:

Retrotransposon; Retroposon; Retroelement; Retrotransposons; Element, Retrovirus-like; Elements, Retrovirus-like; MDG1 Retrotransposon; Retrotransposon, MDG1; Retrotransposons, MDG1; Retrovirus like Elements; Retrovirus-like Element; Transposon, Ty1; Transposons, Ty1; Ty1 Transposons; MDG1 Retrotransposons; Mobile Dispersed Genetic Elements; Retroposons; Retrovirus-like Elements; Ty1 Transposon

Networked: 214 relevant articles (0 outcomes, 5 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Experts

1.	Schulz, Wolfgang A: 6 articles (01/2007 - 01/2005)
2.	Müller, Mirko: 4 articles (01/2007 - 01/2005)
3.	Florl, Andrea R: 4 articles (01/2007 - 01/2005)
4.	Kazazian, Haig H: 3 articles (07/2007 - 08/2002)
5.	Engers, Rainer: 3 articles (01/2007 - 01/2005)
6.	Ramos, K S: 2 articles (07/2010 - 11/2000)
7.	Wendel, Jonathan F: 2 articles (10/2009 - 05/2002)
8.	Kim, A I: 2 articles (09/2009 - 03/2007)
9.	Furini, Antonella: 2 articles (12/2008 - 01/2008)
10.	Petes, Thomas D: 2 articles (05/2008 - 09/2006)

Related Diseases

1.	Neoplasms (Cancer) 12/15/2009 - "The methylation levels of retrotransposons are discretely stratified, with younger elements being highly methylated in healthy tissues, while in tumors, these young elements suffer the most dramatic loss of methylation. " 12/15/2009 - "Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements." 01/01/2009 - "LINE-1 and Alu elements are non-LTR retrotransposons, constituting together over 30% of the human genome and they are frequently hypomethylated in human tumors. " 06/21/2007 - "Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression." 08/01/2006 - "In urothelial cancer, hypermethylation of specific genes and genome-wide hypomethylation, reflected in decreased methylation of LINE-1 retrotransposons, have both been reported, but were never investigated in the same specimens. " Order ALL the reference details at left...
2.	Colorectal Neoplasms (Colorectal Cancer) 03/01/2004 - "This study analysed the methylation status of L1 retrotransposons in colorectal cancer. " 03/01/2004 - "Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue." Order ALL the reference details at left...
3.	Lung Neoplasms (Lung Cancer) 01/01/2009 - "As demethylating agents are now entering lung cancer trials, it is imperative to gain a greater insight into the potential reactivation of silent retrotransposons in order to advance for the clinical utilization of epigenetics in cancer therapy." Order ALL the reference details at left...
4.	Blast Crisis (Blast Phase) 11/03/2005 - "In this study, the methylation status of the LINE-1 (L1) retrotransposon promoter was analysed in CML samples from the chronic-phase (CP, n=140) and the blast crisis (BC, n=47). " Order ALL the reference details at left...
5.	Aneuploidy (Aneuploid) 08/01/1993 - "As part of a study to identify dosage-sensitive modifiers of the white eye colour locus and the retrotransposon, copia, a segmental aneuploid screen was conducted. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	RNA-Directed DNA Polymerase (Reverse Transcriptase)
2.	Retroelements (Retrotransposon)
3.	Proteins (Proteins, Gene)
4.	DNA (Deoxyribonucleic Acid)
5.	RNA (Ribonucleic Acid)
6.	Integrases
7.	Messenger RNA (mRNA)
8.	Ribonuclease H (RNase H)
9.	Amino Acids
10.	Complementary DNA (cDNA)

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 21484 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>